Lishan Aklog,
M.D., Chairman & CEO, to Present November 16, 2023, in New York
NEW
YORK, Nov. 2, 2023 /PRNewswire/ -- Lucid
Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or
the "Company") a commercial-stage, cancer prevention medical
diagnostics company and majority-owned subsidiary of PAVmed Inc.
(Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced its
Chairman and Chief Executive Officer, Dr. Lishan Aklog, will present at the Canaccord
Genuity Medtech, Diagnostics, and Digital Health & Services
Forum on November 16, 2023 at
10:00am EST in New York City.
Management will also be available for one-on-one meetings with
investors at the conference. Investors who are interested in
meeting are encouraged to reach out to their representative at
Canaccord Genuity.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention
medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq:
PAVM). Lucid is focused on the millions of patients with
gastroesophageal reflux disease (GERD), also known as chronic
heartburn, who are at risk of developing esophageal precancer and
cancer. Lucid's EsoGuard® Esophageal DNA Test
is performed on samples collected in a brief, noninvasive office
procedure with its EsoCheck® Esophageal Cell
Collection Device. EsoGuard and EsoCheck are the first and only
commercially available tools designed with the goal of preventing
cancer and cancer deaths through widespread, early detection of
esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more
information about its parent company PAVmed, please visit
www.pavmed.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-present-at-canaccord-genuity-medtech-diagnostics-and-digital-health--services-forum-301975934.html
SOURCE Lucid Diagnostics